AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21392667
Drug: Rapid maxillary
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid maxillary expansion (RME) followed by transpalatal arch (TPA) therapy and extraction of deciduous canines
Trial: 25549517
Drug: No orthodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No orthodontic treatment (control group)
Trial: 19443338
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy with docetaxel plus gemcitabine and concomitant treatment with docetaxel plus carboplatin plus 60 Gy TRT
Trial: 19443338
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with docetaxel plus gemcitabine and concomitant treatment with docetaxel plus carboplatin plus 60 Gy TRT
Trial: 19443338
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of RT treatment
Trial: 19443338
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of induction or consolidation plus concomitant treatment
Trial: 18633754
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg/day for three months
Trial: 12815786
Drug: MAG i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAG i.v. group (25 patients) received daily doses of 2.5 ml of 20% MgSO4 per each 500 ml of transfused fluids for 5 days (day of surgery + 4 days post-surgery)
Trial: 11150431
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (200 mg/m² per cycle) with etoposide and bleomycin
Trial: 11150431
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose cisplatin (100 mg/m² per cycle) with etoposide and bleomycin
Trial: 31243790
Drug: DS-1040 single
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1040 single ascending doses (50, 100, 200, or 400 mg)
Trial: 31243790
Drug: DS-1040 multiple
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1040 multiple ascending doses (100 mg once daily, 200 mg once daily, or 150 mg twice daily)
Trial: 31243790
Drug: DS-1040 single
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1040 single and multiple doses
Trial: 22358132
Drug: LAM plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM plus adefovir (ADV) therapy
Trial: 20585300
Drug: Concurrent Endurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Endurance and Resistance Training (CT)
Trial: 12001038
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg; n=22)
Trial: 10449693
Drug: Active hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active hormone preparations
Trial: 7794146
Drug: Seminar on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seminar on rational prescribing of antibiotics
Trial: 29263353
Drug: 5-day intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day intensive inpatient spa therapy (2 hr/day), exercise (30 min/day), and education (45 min/day)
Trial: 25837016
Drug: Intravenous plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous plus oral pantoprazole therapy (n=252)
Trial: 25837016
Drug: Oral pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pantoprazole alone (n=252)
Trial: 19156149
Drug: Intrapericardial bleomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapericardial bleomycin (BLM) at 15 mg, followed by additional i.p.c. BLM 10 mg every 48 hours.
Trial: 17573751
Drug: Clove oil
RxNorm normalized name: Clove Oil
DrugBank: Clove oil (DB11338)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clove oil 1% cream
Trial: 17573751
Drug: Control (stool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (stool softeners and lignocaine cream 5%)
Trial: 15488040
Drug: 18 gauge
RxNorm normalized name: lancets 18 gauge MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 gauge (G) needle without filter
Trial: 15488040
Drug: 21 gauge
RxNorm normalized name: lancets 21 gauge MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 gauge (G) needle without filter
Trial: 15488040
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between 18G and 21G groups of 2-mL ampoules
Trial: 9407576
Drug: Psychogeriatric intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychogeriatric intervention (multidisciplinary joint treatment by a psychogeriatric team)
Trial: 8485530
Drug: Usual tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual tests for carry-over effects and direct treatment effects
Trial: 31142067
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil 1 mg/kg intravenously for half an hour before operation and lidocaine for periprostatic nerve block (PNB)
Trial: 28248620
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of smoking cues and disgust content
Trial: 22929086
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy for suicidal older men
Trial: 21554734
Drug: Brief Strategic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Strategic Therapy (BST)
Trial: 10229902
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment, 0.05U/kg/day or a maximum of 3U/day s.c., reduced to 0.024±0.004U/kg/day due to side effects.
Trial: 2055059
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ventilatory rates (8 and 16 cycles/min)
Trial: 23323567
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg once daily in the morning
Trial: 23323567
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg once daily in the evening
Trial: 19232035
Drug: Repaglinide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (up to 6 mg/day, 2 mg three times a day)
Trial: 19232035
Drug: Acarbose (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (up to 300 mg/day, 100 mg three times a day)
Trial: 17402796
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg weekly or every other week
Trial: 14985268
Drug: 40% l-menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% l-menthol
Trial: 14985268
Drug: 40% l-menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% l-menthol during A fibre conduction blockade
Trial: 24971433
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) tapering after antithymocyte globulin (h-ATG) for 6 months, tapered over 18 months (total of 2 years)
Trial: 24971433
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) tapering after antithymocyte globulin (h-ATG)
Trial: 23257009
Drug: Jinshuibao capsules
RxNorm normalized name: Jinshuibao
DrugBank: Ophiocordyceps sinensis (DB19288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinshuibao capsules (3 capsules three times a day for 2-3 courses of treatment, each course = 6 weeks)
Trial: 23257009
Drug: Jinshuibao capsules
RxNorm normalized name: Jinshuibao
DrugBank: Ophiocordyceps sinensis (DB19288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinshuibao capsules
Trial: 20973950
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention (phone call, SMS, postal reminder)
Trial: 18515690
Drug: Problem solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem solving therapy-primary care
Trial: 16052083
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg TH9507
Trial: 16052083
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg TH9507
Trial: 25907003
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of solifenacin 6 mg plus TOCAS (0.4 mg)
Trial: 25907003
Drug: TOCAS monotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TOCAS monotherapy (0.4 mg)
Trial: 19073788
Drug: Supplemental iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental iron source (7.6 mg FeSO4 providing 0.9 mg 58Fe as FeSO4)
Trial: 19073788
Drug: Nonheme food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonheme food source (orange‐fleshed sweet potato: 1.4 mg native Fe)
Trial: 17093965
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (7.5 mg) 15 min before MRI
Trial: 17093965
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (1 or 2 mg via nasal spray) immediately prior to MRI
Trial: 11980131
Drug: Allicor 600
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allicor 600 mg/day
Trial: 8147677
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg/d
Trial: 8147677
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg/d + Hydrochlorothiazide 12.5 mg/d
Trial: 8147677
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg/d + Hydrochlorothiazide 25 mg/d
Trial: 31823152
Drug: Radium-223 (55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 (55 kBq/kg) plus abiraterone acetate 1000 mg once daily and prednisone/prednisolone 5 mg twice daily
Trial: 31823152
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus abiraterone acetate 1000 mg once daily and prednisone/prednisolone 5 mg twice daily
Trial: 22177437
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (3200 U/d)
Trial: 9328304
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 10-15 mg/kg/d
Trial: 8405741
Drug: GLP-1 (7-36
RxNorm normalized name: GLP-1 (7-36) amide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 (7-36 amide) infusion at 1.2 pmol x kg‐1 x min‐1
Trial: 3910836
Drug: Prednisone 15
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 15 mg/day
Trial: 25391264
Drug: Short lymphoscintigraphy
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short lymphoscintigraphy protocol (0-2 mL of unfiltered technetium sulphur colloid injected the morning before surgery)
Trial: 25391264
Drug: Long lymphoscintigraphy
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long lymphoscintigraphy protocol (0-2 mL of unfiltered technetium sulphur colloid injected the day before surgery)
Trial: 14987278
Drug: Local KUVA
RxNorm normalized name: Kuvan
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Local KUVA treatment
Trial: 14987278
Drug: Systemic PUVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic PUVA treatment
Trial: 3379743
Drug: Empirical regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical regimen (4.8 million U of aqueous penicillin G procaine intramuscularly and 1.0 g of probenecid orally, followed by 100 mg of oral doxycycline twice daily for seven days)
Trial: 3379743
Drug: Specific therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific therapy for each infection as it was recognized
Trial: 12671333
Drug: Various drugs
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various drugs
Trial: 26436473
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous acetaminophen
Trial: 19230469
Drug: Capsitol‐Enabled Budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsitol‐Enabled Budesonide Inhalation Solution (CBIS) 120 microg twice daily
Trial: 19230469
Drug: Pulmicort Respules
RxNorm normalized name: Pulmicort Respules
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulmicort Respules (budesonide suspension) 500 microg twice daily
Trial: 17035697
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (sodium ferric gluconate complex) 250 mg i.v. weekly x 4
Trial: 17035697
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (ferrous sulfate) 325 mg t.i.d. x 42 days
Trial: 9228490
Drug: Childbirth preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Childbirth preparation with the Lamaze method
Trial: 9228490
Drug: No childbirth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No childbirth preparation
Trial: 3331045
Drug: Imipenem/cilastatin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (0.5 g six hourly)
Trial: 3331045
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ampicillin 0.5 g six hourly, metronidazole 0.5 g eight hourly, gentamicin 80 mg eight hourly)
Trial: 29126824
Drug: Seventeen Days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seventeen Days (treatment intervention; sex education)
Trial: 26690812
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics for the first 6 weeks of therapy
Trial: 26690812
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics for the first 6 weeks of therapy
Trial: 11053761
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (8 weeks)
Trial: 8880820
Drug: Midazolam loading
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam loading dose 0.08 mg.kg‐1
Trial: 8880820
Drug: Midazolam loading
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam loading dose 0.04 mg.kg‐1
Trial: 8880820
Drug: Placebo (0.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.00 mg.kg‐1)
Trial: 8299441
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg 3 times/day)
Trial: 8299441
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg 3 times/day)
Trial: 3522372
Drug: Weekly endoscopic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly endoscopic sclerotherapy
Trial: 29526840
Drug: Average intensity/load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average intensity/load conventional physical therapy (CON) - 60% VO2max
Trial: 25011274
Drug: Safflower treatment
RxNorm normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower treatment group
Trial: 18512752
Drug: Push and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Push and Release Test (P&R) in OFF medication state
Trial: 18512752
Drug: Pull Test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pull Test in OFF medication state
Trial: 18512752
Drug: Push and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Push and Release Test (P&R) in ON medication state
Trial: 18512752
Drug: Pull Test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pull Test in ON medication state
Trial: 12844138
Drug: Theophylline (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (250 mg twice daily)
Trial: 1310834
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (8 mg)
Trial: 1310834
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (4 mg)
Trial: 2485268
Drug: Intravenous angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous angiotensin II infusions (2-16 ng min-1 kg-1)
Trial: 25255799
Drug: Patient oriented
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient oriented decision aid for prioritising treatment goals in diabetes
Trial: 16284203
Drug: CRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT plus medical therapy
Trial: 11910263
Drug: Imipramine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (75 mg twice daily)
Trial: 11910263
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with either fluoxetine or imipramine
Trial: 10622015
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections
Trial: 7852498
Drug: Ovine corticotropin-releasing
RxNorm normalized name: Ovine corticotropin-releasing factor
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovine corticotropin-releasing hormone (CRH) 100 micrograms iv bolus
Trial: 7852498
Drug: Human corticotropin-releasing
RxNorm normalized name: Human corticotropin-releasing factor
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human corticotropin-releasing hormone (CRH) 100 micrograms iv bolus
Trial: 1952268
Drug: Naftidrofuryl (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (600 mg in 250 mL saline infused over six hours)
Trial: 24820288
Drug: Placebo (inert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inert lotion)
Trial: 22930487
Drug: Hydrocortisone 10-0-5-0
RxNorm normalized name: hydrocortisone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 10-0-5-0 mg (treatment A)
Trial: 22930487
Drug: Hydrocortisone 10-5-5
RxNorm normalized name: hydrocortisone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 10-5-5 mg (treatment B)
Trial: 22930487
Drug: Prednisone 5
RxNorm normalized name: prednisone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 5 mg (treatment C)
Trial: 19180569
Drug: Soy supplements
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplements (82 mg/day aglycone equivalents)
Trial: 15144425
Drug: Zonisamide (ZNS)
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide (ZNS) treatment
Trial: 2809097
Drug: 0.10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 mg/kg thrice weekly
Trial: 2809097
Drug: 0.06 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg/kg thrice weekly
Trial: 793005
Drug: Amitriptyline tablets
RxNorm normalized name: amitriptyline Oral Tablet
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline tablets
Trial: 793005
Drug: Fluphenazine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine with nortriptyline (f/n) tablets
Trial: 25935863
Drug: Liraglutide treatment
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide treatment (23 patients)
Trial: 19740396
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive plus rotigotine (2 mg on days 1-3, 3 mg maintenance thereafter)
Trial: 19740396
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patches (instead of rotigotine)
Trial: 19740396
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive plus rotigotine